These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23257949)

  • 1. Genes and cardiovascular risk.
    Faergeman O
    Eur Heart J; 2013 Apr; 34(13):949-50. PubMed ID: 23257949
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
    Hopewell JC; Parish S; Offer A; Link E; Clarke R; Lathrop M; Armitage J; Collins R;
    Eur Heart J; 2013 Apr; 34(13):982-92. PubMed ID: 23100282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
    Mitka M
    JAMA; 2010 Jan; 303(3):211-2. PubMed ID: 20085945
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
    Wong MC; Wang HH; Liu KS
    Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540
    [No Abstract]   [Full Text] [Related]  

  • 5. [The surprising (?) results of IMPROVE-IT].
    Poli A
    G Ital Cardiol (Rome); 2015 May; 16(5):281-3. PubMed ID: 25994463
    [No Abstract]   [Full Text] [Related]  

  • 6. Intensive LDL lowering therapy for prevention of recurrent cardiovascular events: a word of caution.
    Simoons ML; Deckers JW
    Eur Heart J; 2016 Feb; 37(6):520-3. PubMed ID: 26537621
    [No Abstract]   [Full Text] [Related]  

  • 7. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attaining United States and European guideline LDL-C levels with simvastatin in patients with coronary heart disease (the GOALLS study).
    Mikhailidis DP; Wierzbicki AS
    Curr Med Res Opin; 2000; 16(3):205-7. PubMed ID: 11191011
    [No Abstract]   [Full Text] [Related]  

  • 9. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid control in the modern era: an orphan's tale of rags to riches.
    Milani RV; Lavie CJ
    J Am Coll Cardiol; 2013 Dec; 62(23):2185-7. PubMed ID: 24013061
    [No Abstract]   [Full Text] [Related]  

  • 11. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
    Molcányiová A; Stancáková A; Javorský M; Tkác I
    Pharmacol Res; 2006 Sep; 54(3):203-7. PubMed ID: 16737822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cardiovascular disease: the Scandinavian experience.
    Pedersen TR
    Aging (Milano); 1998 Apr; 10(2):167. PubMed ID: 9666222
    [No Abstract]   [Full Text] [Related]  

  • 13. [Lowering LDL cholesterol with Simvastatin. Also, economically reasonable!].
    Internist (Berl); 1995 Aug; 36(8 Suppl):1-4. PubMed ID: 9131077
    [No Abstract]   [Full Text] [Related]  

  • 14. [The current debate on lowering LDL cholesterol with ezetimibe].
    Erdmann E
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1742. PubMed ID: 20812160
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
    Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
    Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Simvastatin].
    Taéron C
    Rev Infirm; 2008 Jun; (141):47-9. PubMed ID: 18669392
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid parameters and cardiovascular events in patients taking statins.
    Martin SS; Jones SR
    JAMA; 2012 Jul; 308(2):131-2; author reply 132-3. PubMed ID: 22782402
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid parameters and cardiovascular events in patients taking statins.
    Brook RD; Rubenfire M
    JAMA; 2012 Jul; 308(2):132; author reply 132-3. PubMed ID: 22782403
    [No Abstract]   [Full Text] [Related]  

  • 20. Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.
    Sniderman AD; Thanassoulis G
    Evid Based Med; 2013 Apr; 18(2):73-4. PubMed ID: 22893654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.